Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.77 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.77 |
| ▸ | TNF | P01375 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826274 | 1.00 | CYP11B1 (0.77) | CYP11B1CYP11B2TNFTDP1HTT | |
| Bromide SCHEMBL31253900 | 0.98 | CYP11B1 (0.75) | CYP11B1CYP11B2TNFTDP1HTT | |
| Hydrochloric Acid SCHEMBL31253891 | 0.98 | CYP11B1 (0.75) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL20550865 | 0.89 | CYP11B1 (0.69) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL28996363 | 0.88 | CYP11B1 (0.67) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL8618130 | 0.88 | CYP11B1 (0.67) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL7212277 | 0.88 | CYP11B1 (0.67) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL30322779 | 0.88 | CYP11B1 (0.67) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL7215799 | 0.88 | CYP11B1 (0.67) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL20715592 | 0.87 | CYP11B1 (0.66) | CYP11B1CYP11B2TNFTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082574-A1 | Metallacycles and methods of making the same | ACADEMIA SINICA (TW) | 2009-03-26 | — | — | US | claimed |
| US-20090082574-A1 | Metallacycles and methods of making the same | ACADEMIA SINICA (TW) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082574-A1 | Metallacycles and methods of making the same | SOD1, PMS2, MEN1 | CYP11B1 95/4885CYP11B2 49/4885TNF 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.